Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan Aphexda Coverage & Prior Aut…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MBP 315.0

    Aphexda (motixafortide) coverage for stem cell mobilization

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MBP 315.0 alerts

    Get alerted when Policy MBP 315.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for Aphexda (motixafortide) when used with filgrastim to mobilize hematopoietic stem cells for autologous transplantation across Geisinger Health Plan lines of business.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAphexda (motixafortide) coverage for stem cell mobilization
    Policy CodePolicy MBP 315.0
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 19, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from the Medical Director or designee and document age ≥18, hematologist/oncologist prescribing, use with filgrastim, and prior failure/intolerance/contraindication to plerixafor when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18min age
    1 monthauth duration
    Requiredauth req
    Filgrastimrequired combo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Listed
    MA UM approvals

    Coverage Criteria

    Initial Therapy (Commercial/Exchange/CHIP/Medicaid)

    Aphexda will be considered medically necessary when ALL of the following are met:

    Commercial/Exchange/CHIP/Medicaid Initial Criteria: Medical record documentation of age greater than or equal to 18 years AND medical record documentation that Aphexda is prescribed by a hematologist or oncologist AND medical record documentation that Aphexda will be used in combination with filgrastim for the mobilization and collection of hematopoietic stem cells for subsequent autologous stem cell transplantation AND medical record documentation of therapeutic failure, intolerance, or contraindication to plerixafor

    Requires prior authorization by Medical Director or designee

    Initial Therapy (Medicare)

    For Medicare, Aphexda will be considered medically necessary when ALL of the following are met:

    Medicare Initial Criteria: Medical record documentation of age greater than or equal to 18 years AND medical record documentation that Aphexda is prescribed by a hematologist or oncologist AND medical record documentation that Aphexda will be used in combination with filgrastim for the mobilization and collection of hematopoietic stem cells for subsequent autologous stem cell transplantation

    Authorization duration: one (1) month

    Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

    No explicit exclusions are stated in the policy text provided in these sections.

    No explicit statements that use of Aphexda (motixafortide) is "not medically necessary" appear in the cited policy excerpts.

    Initial Therapy

    Initial Therapy

    Initial therapy criteria mirror clinical coverage criteria

    Initial Therapy: See coverage criteria: age ≥ 18 years; prescribed by a hematologist or oncologist; intended use in combination with filgrastim for mobilization and collection of hematopoietic stem cells for subsequent autologous stem cell transplantation; for commercial/exchange/CHIP/Medicaid also requires documentation of therapeutic failure, intolerance, or contraindication to plerixafor

    Prior authorization required

    Authorization Duration / Continuation

    Authorization Duration / Continuation

    Authorization Duration: Authorization duration is one (1) month

    Medicaid note: requests not meeting PARP will be evaluated case-by-case

    Provider Actions & Requirements

    Prior Authorization

    Prior authorization required (Medical Director or designee)

    Prior authorization is required for Aphexda and must be obtained from the Medical Director or designee for commercial, exchange, CHIP, and Medicaid lines of business. Coverage is contingent on meeting all listed clinical criteria.

    • PA required by Medical Director or designee
    • Aphexda covered only when all criteria in policy are met
    Prior Authorization

    Medicare prior authorization documentation note

    For Medicare members, prior authorization decisions require documentation that the patient is age ≥18, that Aphexda is prescribed by a hematologist or oncologist, and that it will be used in combination with filgrastim for mobilization and collection of hematopoietic stem cells.

    • Document patient age ≥18
    • Document prescribing provider is a hematologist or oncologist
    • Document planned use in combination with filgrastim for mobilization/collection

    Step Therapy Requirements

    StepRequirementLine(s) of Business
    1Document therapeutic failure, intolerance, or contraindication to plerixaforCommercial, Exchange, CHIP, Medicaid
    StepNoteSupporting Governance
    1No additional step therapy steps specified in the policy textMA UM Committee approval dates: 5/22/24; 4/29/25

    Site of Care

    Note

    Site-of-care: infusion center — no restrictions specified

    No site-of-care restrictions are specified for infusion center use in the provided chunks.

    Background

    Motixafortide (Aphexda) is a selective CXCR4 antagonist that binds CXCR4 with high affinity and prolonged receptor occupancy, inhibiting CXCR4 interaction with SDF1α/CXCL12 and mobilizing hematopoietic stem and progenitor cells from the bone marrow into peripheral blood when used in combination with filgrastim; mobilized CD34+ cells have engraftment capacity and are used to facilitate collection for subsequent autologous stem cell transplantation.

    Definitions

    Motixafortide mechanism
    Mechanism of actionMotixafortide selectively inhibits CXCR4 binding to SDF1α/CXCL12 expressed by bone marrow stromal cells, resulting in mobilization of hematopoietic stem and progenitor cells from bone marrow into peripheral blood; binds CXCR4 with high affinity and prolonged receptor occupancy
    Clinical effectMobilized CD34+ cells are capable of engrafting with extended repopulating capacity (observed in animal models)
    Target receptorC-X-C motif chemokine receptor 4 (CXCR4)
    Ligand interaction blockedStromal cell-derived factor-1-alpha (SDF1α) / CXCL12 binding to CXCR4
    Medical Necessity
    DefinitionMedical Necessity means covered services that are appropriate for the member's symptoms/diagnosis, provided for direct care and treatment, in accordance with current standards of good medical treatment, not primarily for convenience, and the most appropriate level of service
    Policy Summary
    PayerGeisinger Health Plan
    PolicyAphexda (motixafortide) coverage for stem cell mobilization
    Policy CodePolicy MBP 315.0
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 19, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from the Medical Director or designee and document age ≥18, hematologist/oncologist prescribing, use with filgrastim, and prior failure/intolerance/contraindication to plerixafor when applicable.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyAuthorization Duration / ContinuationProvider Actions & RequirementsStep Therapy RequirementsSite of CareBackgroundDefinitions
    Note

    PA oversight and UM governance documented

    Utilization management oversight is noted by MA UM Committee approvals on 5/22/24 and 4/29/25; these entries indicate PA governance though specific additional PA procedures are not detailed within these chunks.

    • MA UM Committee approval dates: 5/22/24, 4/29/25
    Step Therapy

    Step therapy: plerixafor failure/intolerance/contraindication required

    Prior authorization requires evidence of prior therapeutic failure, intolerance, or contraindication to plerixafor for commercial, exchange, CHIP, and Medicaid before Aphexda is considered medically necessary.

    • Must document therapeutic failure, intolerance, or contraindication to plerixafor
    Step Therapy

    No other step therapy requirements specified

    No additional step therapy requirements or steps are specified in the referenced chunks.

    Documentation Required

    Required medical record documentation

    Medical record documentation must include patient age ≥18, the prescribing provider specialty (hematologist or oncologist), planned use in combination with filgrastim for mobilization and collection of hematopoietic stem cells for autologous transplant, and — for commercial/CHIP/Medicaid — documentation of therapeutic failure, intolerance, or contraindication to plerixafor.

    • Patient age ≥18 documented
    • Prescribing provider is hematologist or oncologist
    • Planned use with filgrastim documented
    • For commercial/CHIP/Medicaid: prior failure/intolerance/contraindication to plerixafor documented
    Documentation Required

    Document header / policy title shown

    Document header shows the policy title (Aphexda [motixafortide]); no additional or alternate documentation requirements are specified in the referenced chunks.

    Denial Risk

    Denial triggers: missing required documentation

    Lack of documentation that Aphexda is prescribed by a hematologist or oncologist, or that it will be used in combination with filgrastim for mobilization and collection of hematopoietic stem cells, or absence of documentation of therapeutic failure/intolerance/contraindication to plerixafor may trigger denial.

    • Missing provider specialty (hematologist/oncologist)
    • Missing plan to use with filgrastim
    • Missing documentation of plerixafor failure/intolerance/contraindication (where required)
    Note

    No other provider actions specified

    No additional provider actions are stated in the referenced chunks beyond the prior authorization, documentation, and step therapy items already described.

    Application to hospitalizationWhen applied to hospitalization, means the member requires acute care as an inpatient and cannot receive safe or adequate care as an outpatient
    Provider contextDetermination is made by the Plan for services rendered by a health care provider
    Definitions
    Motixafortide (term)A CXCR4 antagonist that mobilizes hematopoietic stem and progenitor cells from bone marrow into peripheral blood by inhibiting CXCR4 binding to SDF1α/CXCL12; binds CXCR4 with high affinity and prolonged receptor occupancy
    Medical Necessity (term)Services appropriate for the member's condition, provided for direct care, in accordance with current standards, not primarily for convenience, and the most appropriate level of service
    Policy review notePolicy includes review metadata (Reviewed:), and eligibility/contract specific benefit limitations may apply as stated elsewhere in the document